Engene Holdings INC 8-K filings

enGene Holdings Inc. has updated its corporate presentation, emphasizing the potential of its lead program, detalimogene voraplasmid, for treating non-muscle invasive bladder cancer.

enGene Holdings Inc. has appointed Ron Cooper as its new Chief Executive Officer, effective July 22, 2024, as part of a planned succession.

enGene Holdings Inc. reported its second quarter 2024 financial results and announced an expansion of its EG-70 clinical program into high-risk papillary-only non-muscle invasive bladder cancer.

enGene Holdings Inc. shareholders approved amendments to the company's 2023 Incentive Equity Plan at the annual meeting, including changes to the evergreen provision and share reserve.

enGene Holdings Inc. announced its first quarter 2024 financial results, highlighted by a $200 million private financing and progress in its pivotal Phase 2 LEGEND study for EG-70.

enGene Holdings Inc. has successfully raised $200 million through a private placement and announced the upcoming resignation of its CEO, Jason Hanson, upon the appointment of a successor.

enGene Holdings announced its full year 2023 financial results, highlighted by clinical progress in its bladder cancer study and a successful transition to a public company.